drugset / Trial / NCT03180528
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Phase 2
Completed
30 enrolled
Kavita Sarin
American Skin Association · collabMedivir · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.
Timeline
- Start
- 2018-07-07
- Primary completion
- 2020-07-07
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remetinostat | Small molecule | 1 % | Topical |